KMT2D and diffuse large B-cell lymphoma: A study from Liu et al. revealed somatic KMT2D mutations in about 19% of patients suffering from diffuse large B cell lymphoma (DLBCL) promoting tumor progression (Liu Q. X. et al., 2024).